EJC paediatric oncology最新文献

{"title":"Malignant extracranial germ cell tumors in the Netherlands between 1990 and 2018: Stable incidence and improved survival","authors":"Caroline C.C. Hulsker ,&nbsp;Maya Schulpen ,&nbsp;Annelies M.C. Mavinkurve-Groothuis ,&nbsp;Otto Visser ,&nbsp;József Zsiros ,&nbsp;Marc H.W. Wijnen ,&nbsp;Ronald R. de Krijger ,&nbsp;Annette H. Bruggink ,&nbsp;Leendert H.J. Looijenga ,&nbsp;Henrike E. Karim-Kos ,&nbsp;Alida F.W. van der Steeg","doi":"10.1016/j.ejcped.2024.100148","DOIUrl":"https://doi.org/10.1016/j.ejcped.2024.100148","url":null,"abstract":"<div><h3>Background</h3><p>Population-based studies assessing long-term patterns of incidence and disease characteristics of germ cell tumors (GCTs) in children are scarce. We investigated incidence and survival trends of malignant extracranial GCTs in children using population-based nationwide data from the Netherlands.</p></div><div><h3>Methods</h3><p>All malignant extracranial GCTs diagnosed in patients aged 0–18 years between 1990 and 2018 were selected from the Netherlands Cancer Registry. Incidence rates were calculated as the average annual number of cases per 1 million person-years. Five-year overall survival (OS) was calculated.</p></div><div><h3>Results</h3><p>A total of 815 cases were identified. Gonadal GCTs (n=665, testis n=485, ovarian n=180) were more common than extragonadal GCTs (n=149). Stage distribution for testicular and extragonadal GCTs shifted between 1990 and 2004 and 2005–2018 towards more localized disease. The overall incidence remained stable over time, but a significant increase was noted for extragonadal GCTs in the 0–9 years age group. Survival of extragonadal GCTs (5-year OS 84.1%, 95% CI 77.1–89.1), in particular mediastinal GCTs (5-year OS 66.7%, 95% CI 45.7–81.1), was lower than that of gonadal GCTs (5-year OS testis 95.0%, 95% CI 92.7–96.7;ovary 97.8%, 95% CI 94.2–99.2). The 5-year OS of our entire cohort was 93.6% (95% CI 91.7–95.1). Five-year OS significantly increased from 89.5% (95% CI 86.1–92.2) in 1990–2004–97.4% (95% CI 95.3–98.5) in 2005–2018.</p></div><div><h3>Conclusions</h3><p>Although the incidence of all malignant pediatric extracranial GCTs remained stable during 1990–2018, an increase was observed for extragonadal GCTs in younger children (0–9 years). There was a shift towards more localized disease for testicular and extragonadal GCTs. Five-year OS increased over time exceeding 90% (91.4%, 95% CI 82.7–95.8) in the most recent diagnostic period. Mediastinal GCTs had the lowest OS, supporting the need for future research.</p></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"3 ","pages":"Article 100148"},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772610X24000072/pdfft?md5=503469431d7200fe24642a6af61277f3&pid=1-s2.0-S2772610X24000072-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139999308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How we approach early phase clinical trial and off-label therapy consults in pediatric oncology: The New Agents and Innovative Therapy (NAIT) team experience","authors":"Gabriel Revon-Rivière,&nbsp;Pauline Tibout,&nbsp;Jennifer Cabral,&nbsp;Aiman Siddiqi,&nbsp;Ashley Doka,&nbsp;Denise Mills,&nbsp;Karen Fung,&nbsp;Sandra Judd,&nbsp;Daniel A. Morgenstern,&nbsp;Sarah Cohen-Gogo","doi":"10.1016/j.ejcped.2024.100154","DOIUrl":"https://doi.org/10.1016/j.ejcped.2024.100154","url":null,"abstract":"<div><p>In the context of hard-to-cure disease, pediatric oncologists may have to explore novel therapy options and explain their rationale, risks and constraints to patients and caregivers. The New Agents and Innovative Therapy (NAIT) program at Hospital for Sick Children in Toronto facilitates patient enrollment in clinical trials as well as access to innovative therapies outside of clinical trials. Here, we summarize our experience with helping patients, caregivers, and their primary oncology team navigate information and access to new therapeutic options through enrollment in clinical trials but also off-label and compassionate use. We expose our approach to exploring clinical trial and other therapy options. We share lessons learned from clinical practice regarding the specific role of NAIT consultant, as opposed to the primary oncologist or the disease expert. We expand on ways to communicate regarding the objectives of early phase clinical trials, their methods and the important commitment asked from participants. We describe our views on equipoise, uncertainty and hope in this very specific practice. We support a model of shared decision making and empowerment of patients and caregivers. We also detail the use, benefits and challenges of virtual care applied to NAIT consults. Overall, we hope to contribute and facilitate the NAIT practice not only for trained trialists but also less-specialized teams.</p></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"3 ","pages":"Article 100154"},"PeriodicalIF":0.0,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772610X24000138/pdfft?md5=a358b55bee4d9dda2b38d12d51888a4b&pid=1-s2.0-S2772610X24000138-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140016032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergent and underexplored oncolytic viruses for treating pediatric central nervous system tumors","authors":"Isabela Granha ,&nbsp;Gustavo Sartorelli ,&nbsp;Oswaldo Keith Okamoto ,&nbsp;Elisa Helena Farias Jandrey","doi":"10.1016/j.ejcped.2024.100151","DOIUrl":"https://doi.org/10.1016/j.ejcped.2024.100151","url":null,"abstract":"<div><p>High-grade pediatric Central Nervous System (CNS) tumors are frequent, highly aggressive, and the most common cause of cancer-associated death in children. Due to their unique features, such as heterogeneous tumor molecular characteristics, distinct microenvironment, challenging anatomical localization and the presence of the blood brain barrier, brain tumors are especially difficult to treat and often present a poor response to standard therapies (surgery, radio and chemotherapy). Because of that, there is a need for investigating more effective therapeutic approaches and, within this context, Oncolytic Viruses (OVs) have emerged as a promising new class of immunotherapeutic agents. These viruses have a natural or artificial tropism for cancer cells and their central mechanism of action is the direct oncolytic effect followed by activation of the immune response. As a consequence, the OV therapy can be safer than traditional approaches, and its use may help overcome some pediatric CNS tumor treatment challenges. In this review, we initially examine the potential therapeutic advantages that are intrinsically related to OVs infection mechanism. Then, we address the surpassing resistance mechanisms of available treatments for pediatric brain tumors and present some challenges to be taken into consideration in clinical application. We next provide an overview of preclinical studies focusing on the mechanisms of infection and also <em>in vitro</em> and <em>in vivo</em> findings of emergent and underexplored OVs, namely Zika virus, Measles virus, Reovirus, Poliovirus, Seneca Valley virus, Vaccinia virus, Myxoma virus and Parvovirus. Finally, we summarize the latest clinical trials using these underexplored OVs against pediatric solid tumors.</p></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"3 ","pages":"Article 100151"},"PeriodicalIF":0.0,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772610X24000102/pdfft?md5=6bcf2b90582bd93a2e40bf7c254884c3&pid=1-s2.0-S2772610X24000102-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139998919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CAR T-cells for T-cell acute lymphoblastic leukemia","authors":"Marie Emilie Dourthe ,&nbsp;André Baruchel","doi":"10.1016/j.ejcped.2024.100150","DOIUrl":"https://doi.org/10.1016/j.ejcped.2024.100150","url":null,"abstract":"<div><p>T-cell acute lymphoblastic leukemia (T-ALL) has a dismal prognosis in case of relapsed or refractory disease. Contrary to B-ALL, few immunotherapies are available for T-ALL. Use of autologous CAR T-cells is challenging due to shared antigen between leukemic and normal T-cells responsible for fratricide and T-cell aplasia in case of persistence of CAR T-cells. Moreover, risk of contamination of the apheresis product by lymphoblasts remains an issue. To counteract these challenges several methods are used to edit T-cell such as protein expression blocker, CRISPR/Cas9 and base-editing. Other possibility is to use autologous T-cells naturally selected <em>in vitro</em> or donor-derived T-cells allowing gene edition and reduction of the risk of graft vs host disease. Encouraging results are obtained in preclinical and clinical studies for early response rate but several questions remain. Is the persistence of these cells requiring for maintaining the remission? Is it feasible to recover a target-negative T-cell population without risk of profound immunosuppression? Has an allogeneic stem cell transplantation to be planned for patients after CAR T-cells infusion? What about the risk of engineered T-cells in the long term?</p></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"3 ","pages":"Article 100150"},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772610X24000096/pdfft?md5=43b91a189526444cfcf248b29b55d17c&pid=1-s2.0-S2772610X24000096-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139936597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome editing approaches for universal chimeric antigen receptor T cells","authors":"Avijeet Kumar Mishra,&nbsp;Waseem Qasim","doi":"10.1016/j.ejcped.2024.100149","DOIUrl":"https://doi.org/10.1016/j.ejcped.2024.100149","url":null,"abstract":"<div><p>Autologous chimeric antigen receptor (CAR) T cell therapy has revolutionised the management of certain B-cell malignancies. However, as bespoke therapies, challenges include complex manufacturing logistics and risks ranging from suboptimal harvests to inadvertent transduction and masking of blast populations. Premanufactured, ready -to -use allogeneic CAR T cells could mitigate some of these hurdles if barriers created by HLA (Human leukocyte antigen) mismatching can be addressed. Genome editing to disrupt TCRαβ (T-cell receptor αβ) expression has been shown to be effective in addressing alloreactivity and avoiding graft versus host disease (GVHD). Platforms including transcription activator-like effector nucleases (TALENs), homing endonucleases and clustered regularly interspersed short palindromic repeats (CRISPR) / Cas9 have allowed multiplex editing of TCR genes in combination with CD52, the target antigen of alemtuzumab, as a strategy to evade lymphodepletion used to prevent host v graft rejection effects. Alternative approaches have targeted pathways to prevent HLA expression on donor T cells, and have also allowed targeted insertion of CAR genes, including placing transgene expression under the control of endogenous transcriptional machinery. These tools have rapidly progressed to clinical trials, and applications have extended beyond B-cell malignancies, showing promising early results in other settings, including relapsed/refractory(r/r) T-cell leukaemia. Short term immunological effects and toxicities have been generally manageable, and long-term monitoring is ongoing to help build confidence in safety over time.</p></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"3 ","pages":"Article 100149"},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772610X24000084/pdfft?md5=009b31ff0c5884814369171601da3f60&pid=1-s2.0-S2772610X24000084-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139986335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"General support of physical exercise programs in pediatric oncology but differences in perception by childhood cancer care professionals at European and North-African/Arab centers","authors":"Moatasem El-Ayadi ,&nbsp;Kyra Druivenga ,&nbsp;Thomas Perwein ,&nbsp;Gunther Nussbaumer ,&nbsp;Filippo Spreafico ,&nbsp;Maura Massimino ,&nbsp;Shady Fadel ,&nbsp;Nisreen Amayiri ,&nbsp;Nisrine Khoubila ,&nbsp;Laila Hessissen ,&nbsp;Omar Chamdine ,&nbsp;Natàlia Rodríguez ,&nbsp;Gemma Calaf Valls ,&nbsp;Andres Morales la Madrid ,&nbsp;Christine Dahl ,&nbsp;Darren Hargrave ,&nbsp;Elwira Szychot ,&nbsp;Simon Bailey ,&nbsp;Dannis G. van Vuurden ,&nbsp;Martin Benesch ,&nbsp;Christof M. Kramm","doi":"10.1016/j.ejcped.2024.100147","DOIUrl":"https://doi.org/10.1016/j.ejcped.2024.100147","url":null,"abstract":"<div><h3>Purpose</h3><p>To explore the perception of physical exercise programs for pediatric oncology patients among childhood cancer care professionals. We also aimed at comparing such perceptions between cultures. Healthcare professionals’ endorsement may be essential for initiating and promoting such programs.</p></div><div><h3>Methods</h3><p>An anonymous survey was designed and administered voluntarily to childhood cancer care professionals (including pediatric oncologists, nurses, and physiotherapists) in European, North-African and Arab pediatric oncology centers.</p></div><div><h3>Results</h3><p>Five-hundred-and twenty-eight professionals from 14 sites answered the survey. Most respondents considered physical exercise programs as a suitable therapeutic approach for pediatric cancer patients with a potential positive contribution to survival (81%), wellbeing (82%), quality of life (80%), and self-esteem (75%). 91% of respondents would also support the future introduction of physical exercise programs into standard pediatric oncological care. There was a comparatively higher appreciation of physical exercise programs among European centers compared to North-African / Arab centers.</p></div><div><h3>Conclusion</h3><p>We registered a broad acceptance of physical exercise programs among all European and North-African / Arab childhood cancer care professionals. The positive perception was independent of any pre-existing experience with such programs and seems therefore representative. This finding may encourage the further promotion of physical exercise programs in pediatric oncology.</p></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"3 ","pages":"Article 100147"},"PeriodicalIF":0.0,"publicationDate":"2024-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772610X24000060/pdfft?md5=dc315874b71ece9e44492cf63c376405&pid=1-s2.0-S2772610X24000060-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139737844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of current European practice for the management of patients with intracranial germ cell tumours","authors":"Manuel Diezi ,&nbsp;Barry Pizer ,&nbsp;Matthew J. Murray ,&nbsp;on behalf of the SIOP-Europe Brain Tumour Group - Central Nervous System (CNS) Germ Cell Tumour (GCT) Subgroup","doi":"10.1016/j.ejcped.2024.100146","DOIUrl":"10.1016/j.ejcped.2024.100146","url":null,"abstract":"<div><p>Central nervous system germ cell tumours (CNS GCT) form a diverse group of tumour entities, including germinoma, yolk sac tumour, embryonal carcinoma, choriocarcinoma, teratoma, and mixed tumours. Incidence peaks in the second decade, predominantly in males. Incidence rates vary globally, higher in Asia, suggesting genetic factors are important. CNS GCTs split into pure germinomas and non-germinomatous GCTs (NGGCT), influencing prognosis/treatment. Serum and CSF markers (alpha-fetoprotein, human chorionic gonadotropin) aid diagnosis, potentially avoiding neurosurgical biopsy. Histological features are distinguished by immunohistochemical staining. Studies have identified specific microRNAs in serum/CSF at diagnosis as promising biomarkers. Mutated pathways have been identified, but targeted therapies have shown limited success to date. Diagnosis involves recognising symptoms like raised intracranial pressure, endocrinological, and ophthalmological disturbances. MRI imaging is crucial for diagnosis and guiding treatment decisions. Treatment strategies vary, as pure germinomas respond well to chemotherapy and radiotherapy, or craniospinal radiotherapy alone, with excellent outcomes; in contrast NGGCTs demand aggressive combined chemo-radiotherapy, yielding generally inferior outcomes. Teratomas are typically chemo-/radio-resistant, requiring surgical intervention. Relapses need re-staging and (re-)biopsy consideration. Relapsed germinomas, though rare, may be cured with standard-dose chemotherapy and re-irradiation, or high-dose chemotherapy with stem-cell-transplantation, with/without further radiation. The more commonly observed NGGCT relapses have poor prognosis, even with thiotepa-based high-dose chemotherapy and stem-cell-transplantation delivered with curative intent. In summary, CNS GCT management integrates clinical, radiological, and histological findings, along with serum and CSF markers, for tailored treatment. Ongoing research aims to incorporate microRNA markers and molecular pathology for improved diagnosis, prognostication, and therapeutic intervention.</p></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"3 ","pages":"Article 100146"},"PeriodicalIF":0.0,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772610X24000059/pdfft?md5=a38d7e7f06eaebc345e355e75f9cd4f3&pid=1-s2.0-S2772610X24000059-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139885760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of current European practice for the management of patients with intracranial germ cell tumours","authors":"Manuel Diezi, Barry Pizer, Matthew J. Murray","doi":"10.1016/j.ejcped.2024.100146","DOIUrl":"https://doi.org/10.1016/j.ejcped.2024.100146","url":null,"abstract":"","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"66 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139826065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical presentation and outcome of invasive mould disease in paediatric patients with acute lymphoblastic leukaemia","authors":"Didi Bury ,&nbsp;Corline E.J. Parmentier ,&nbsp;Wim J.E. Tissing ,&nbsp;Rob Pieters ,&nbsp;Louis J. Bont ,&nbsp;Roger J. Brüggemann ,&nbsp;Tom F.W. Wolfs","doi":"10.1016/j.ejcped.2024.100143","DOIUrl":"10.1016/j.ejcped.2024.100143","url":null,"abstract":"<div><h3>Background</h3><p>Childhood acute lymphoblastic leukaemia (ALL) cure rates have improved, but invasive mould disease (IMD) remains a life-threatening complication. Here, we evaluate the epidemiology, clinical presentation, treatment and outcome of IMD in paediatric patients with ALL.</p></div><div><h3>Methods</h3><p>Patients (1–18 years) treated according to the Dutch Childhood Oncology Group (DCOG) ALL-11 protocol from 2012–2021 were analysed for probable and proven IMD. Data was extracted from the Dutch national registry and the electronic health care system.</p></div><div><h3>Results</h3><p>Among 643 patients with ALL, 47 (7.3%) were diagnosed with a probable (n = 29) or proven (n = 18) IMD. Aspergillosis was diagnosed in 42 (89%) patients. Forty-one episodes (87%) occurred during the induction (n = 20) and first consolidation (n = 21) course. The median age at ALL diagnosis was 5 years [IQR 3–10] in the overall group versus 14 years [IQR 7–16] in the IMD group. Two-third of the patients did not receive mould-active prophylaxis. The most prevalent clinical symptoms at presentation were persistent fever and respiratory symptoms. The lungs were the most common site of infection with involvement in 44 (94%) patients, followed by the CNS in 16 (34%) patients. The 6-week and 12-week mortality rate after IMD diagnosis was 10.6% and 14.9%, respectively.</p></div><div><h3>Discussion and conclusion</h3><p>In our paediatric cohort a notable incidence of probable and proven IMD was observed during the early stages of treatment. Remarkable is the high frequency of CNS involvement. These findings highlight the importance of effective prophylactic strategies and warrant early brain imaging.</p></div>","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"3 ","pages":"Article 100143"},"PeriodicalIF":0.0,"publicationDate":"2024-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772610X24000023/pdfft?md5=dcf6a8ca939cc20cc7d0a0e04a505189&pid=1-s2.0-S2772610X24000023-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139635670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Very rare tumors are not so rare in children","authors":"Daniel Orbach ,&nbsp;Ines Brecht ,&nbsp;Andrea Ferrari","doi":"10.1016/j.ejcped.2024.100144","DOIUrl":"10.1016/j.ejcped.2024.100144","url":null,"abstract":"","PeriodicalId":94314,"journal":{"name":"EJC paediatric oncology","volume":"3 ","pages":"Article 100144"},"PeriodicalIF":0.0,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772610X24000035/pdfft?md5=0868c338a1dd9de16cdb13cdbec5f29f&pid=1-s2.0-S2772610X24000035-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139539281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}